OBJECTIVE: Wide biotechnological investigations of only a limited number of seaweed lectins have been performed. We previously demonstrated the anti-nociceptive and anti-inflammatory effects of a lectin isolated from the green seaweed Caulerpa cupressoides var. lycopodium (CcL). Herein, we further studied the mechanisms of action of CcL. METHODS: Classical acute inflammation models induced by different flogistic agents were used to evaluate the anti-inflammatory action of CcL. CcL was injected locally into the rat paw to verify a possible pro-inflammatory outcome. RESULTS: CcL (0.1, 1 or 10 mg/kg; i.v.) reduced the carrageenan-induced rat paw edema and neutrophilic infiltration, which was not altered by either mucin (inhibitor of CcL carbohydrate-binding site) or ZnPP-IX (specific HO-1 inhibitor). Immunohistochemical analyses showed that CcL (1 mg/kg) reduced the expression of the cytokines IL-1β, TNF-α, IL-6 and COX-2. CcL (0.1, 1 or 10 mg/kg) inhibited dextran, and CcL (1 mg/kg) inhibited histamine-induced rat paw edema. Both effects were reversed by mucin inhibition. CcL (1 mg/kg) was ineffective for the treatment of serotonin- and bradykinin-induced rat paw edema. When injected via the i.pl. route, CcL (10 mg/kg) elicited rat paw edema involving a wide range of mediators. CONCLUSIONS: The anti-inflammatory action of CcL involves the inhibition of IL-1β, TNF-α, IL-6 and COX-2 expression and histamine H1 receptors. When locally administered, CcL exerts pro-inflammatory actions.
OBJECTIVE: Wide biotechnological investigations of only a limited number of seaweed lectins have been performed. We previously demonstrated the anti-nociceptive and anti-inflammatory effects of a lectin isolated from the green seaweed Caulerpa cupressoides var. lycopodium (CcL). Herein, we further studied the mechanisms of action of CcL. METHODS: Classical acute inflammation models induced by different flogistic agents were used to evaluate the anti-inflammatory action of CcL. CcL was injected locally into the rat paw to verify a possible pro-inflammatory outcome. RESULTS:CcL (0.1, 1 or 10 mg/kg; i.v.) reduced the carrageenan-induced rat paw edema and neutrophilic infiltration, which was not altered by either mucin (inhibitor of CcL carbohydrate-binding site) or ZnPP-IX (specific HO-1 inhibitor). Immunohistochemical analyses showed that CcL (1 mg/kg) reduced the expression of the cytokines IL-1β, TNF-α, IL-6 and COX-2. CcL (0.1, 1 or 10 mg/kg) inhibited dextran, and CcL (1 mg/kg) inhibited histamine-induced rat paw edema. Both effects were reversed by mucin inhibition. CcL (1 mg/kg) was ineffective for the treatment of serotonin- and bradykinin-induced rat paw edema. When injected via the i.pl. route, CcL (10 mg/kg) elicited rat paw edema involving a wide range of mediators. CONCLUSIONS: The anti-inflammatory action of CcL involves the inhibition of IL-1β, TNF-α, IL-6 and COX-2 expression and histamine H1 receptors. When locally administered, CcL exerts pro-inflammatory actions.
Authors: Flávio da S Bitencourt; Jozi G Figueiredo; Mário R L Mota; Carla C R Bezerra; Priscila P Silvestre; Marcus R Vale; Kyria S Nascimento; Alexandre H Sampaio; Celso S Nagano; Silvana Saker-Sampaio; Wladimir R L Farias; Benildo S Cavada; Ana M S Assreuy; Nylane M N de Alencar Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2008-02-13 Impact factor: 3.000
Authors: Renata Line da Conceição Rivanor; Hellíada Vasconcelos Chaves; Danielle Rocha do Val; Alice Ramos de Freitas; Jonas Cavalcante Lemos; José Ariévilo Gurgel Rodrigues; Karuza Maria Alves Pereira; Ianna Wivianne Fernandes de Araújo; Mirna Marques Bezerra; Norma Maria Barros Benevides Journal: Int Immunopharmacol Date: 2014-04-24 Impact factor: 4.932
Authors: Ana L G Quinderé; Bruno P Fontes; Edfranck de S O Vanderlei; Ismael N L de Queiroz; José A G Rodrigues; Ianna W F de Araújo; Roberta J B Jorge; Dalgimar B de Menezes; Antonio A R e Silva; Hellíada V Chaves; Janaina S A M Evangelista; Mirna M Bezerra; Norma M B Benevides Journal: Pharmacol Rep Date: 2013 Impact factor: 3.024
Authors: G M Cunha; P J Bezerra; M D Saldanha; M C Cavalcante; V M De Brun; G S Viana Journal: Pharmacol Biochem Behav Date: 2000-08 Impact factor: 3.533
Authors: Ana Maria Sampaio Assreuy; Daniel Magalhães Gomes; Michelle Soares Josino da Silva; Valeska Martins Torres; Rômmulo Celly Lima Siqueira; Alana de Freitas Pires; David Neil Criddle; Nylane Maria Nunes de Alencar; Benildo Sousa Cavada; Alexandre Holanda Sampaio; Wladimir Ronald Lobo Farias Journal: Biol Pharm Bull Date: 2008-04 Impact factor: 2.233
Authors: Javier Echave; Paz Otero; Paula Garcia-Oliveira; Paulo E S Munekata; Mirian Pateiro; Jose M Lorenzo; Jesus Simal-Gandara; Miguel A Prieto Journal: Antioxidants (Basel) Date: 2022-01-17